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Abstract: Epidermolysis bullosa is a group of genetic skin conditions characterized by abnormal
skin (and mucosal) fragility caused by pathogenic variants in various genes. The disease severity
ranges from early childhood mortality in the most severe types to occasional acral blistering in the
mildest types. The subtype and severity of EB is linked to the gene involved and the specific variants
in that gene, which also determine its mode of inheritance. Current treatment is mainly focused
on symptomatic relief such as wound care and blister prevention, because truly curative treatment
options are still at the preclinical stage. Given the current level of understanding, the broad spectrum
of genes and variants underlying EB makes it impossible to develop a single treatment strategy
for all patients. It is likely that many different variant-specific treatment strategies will be needed
to ultimately treat all patients. Antisense-oligonucleotide (ASO)-mediated exon skipping aims to
counteract pathogenic sequence variants by restoring the open reading frame through the removal
of the mutant exon from the pre-messenger RNA. This should lead to the restored production of
the protein absent in the affected skin and, consequently, improvement of the phenotype. Several
preclinical studies have demonstrated that exon skipping can restore protein production in vitro, in
skin equivalents, and in skin grafts derived from EB-patient skin cells, indicating that ASO-mediated
exon skipping could be a viable strategy as a topical or systemic treatment. The potential value of
exon skipping for EB is supported by a study showing reduced phenotypic severity in patients who
carry variants that result in natural exon skipping. In this article, we review the substantial progress
made on exon skipping for EB in the past 15 years and highlight the opportunities and current
challenges of this RNA-based therapy approach. In addition, we present a prioritization strategy for
the development of exon skipping based on genomic information of all EB-involved genes.
Keywords: epidermolysis bullosa; exon skipping; antisense oligonucleotide
1. Epidermolysis Bullosa
Epidermolysis bullosa (EB) is a group of rare skin conditions caused by variants
in genes coding primarily for structural proteins involved in skin integrity and cell–cell
adhesion such as keratins, integrins, laminins, plakins, and collagens. Depending on the
gene involved, pathogenic variants can lead to a multitude of EB subtype-specific skin and
sometimes extracutaneous complications [1,2]. The four main types of EB are EB simplex
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(EBS), Junctional EB (JEB), Dystrophic EB (DEB), and Kindler EB (KEB), with some of the
types further divided into multiple subtypes (Table 1). In EBS, blisters form in the basal
keratinocyte layer of the epidermis. The most important EBS genes are KRT5 (Keratin 5,
OMIM 148040) and KRT14 (Keratin 14, OMIM 148040), which together dimerize to form the
intermediate filaments that serve as the cytoskeleton of basal keratinocytes. Structurally
weakened keratinocytes are prone to damage due to mechanical friction, which in turn
causes cytolysis and blistering within the basal epidermis. EBS can present in a localized,
intermediate, or generalized subtype. In localized EBS (OMIM 131800), blistering is usually
limited to the hands and feet. In intermediate and generalized EBS (OMIM 131760),
blistering can occur all over the body, and this is accompanied by a typical inflammatory
aspect and herpetiform distribution of the lesions in generalized EBS. Other rarer forms
of EBS are caused by variants in the genes KLHL24 (Kelch-like family member 24, OMIM
617294), EXPH5 (Exophilin 5, OMIM 612878), PLEC (Plectin, OMIM 601282), DST (Dystonin,
OMIM 615425), and CD151 (Tetraspanin-24, OMIM 609057). In JEB, blistering occurs within
the lamina lucida zone of the cutaneous basement membrane zone. JEB is caused by defects
in laminin 332, integrin α6β4, or type XVII collagen that are caused by pathogenic variants
in the LAMA3 (Laminin α3 chain, OMIM 600805), LAMB3 (Laminin β3 chain, OMIM
150310), LAMC2 (Laminin γ2 chain, OMIM 150292), ITGA6 (Integrin α6, OMIM 226730),
ITGB4 (Integrin β4, OMIM 147557), or COL17A1 (Type XVII Collagen, OMIM 113811)
genes. These proteins facilitate the adhesion of basal keratinocytes to the collagen in the
upper dermis. There are two main JEB subtypes that differ in severity: intermediate and
severe JEB. Intermediate JEB (OMIM 226650) is characterized by generalized skin blistering,
hypergranulation, and wound-healing problems, nail loss, and frequently permanent hair
loss. In severe JEB (formerly known as Herlitz type, OMIM 226700), in addition to blistering
over the entire body, mucosal membranes such as the airway and digestive tract are also
affected, and patients usually die within one or two years after birth. In DEB, blistering
occurs just below the lamina densa of the basement membrane zone due to pathogenic
variants in COL7A1, which encodes the type VII collagen molecule that self-aggregates to
form anchoring fibrils that secure attachment of the epidermis to the underlying dermis.
DEB can be divided into dominantly (DDEB, OMIM 131750) or recessively (RDEB, OMIM
226600) inherited DEB. DEB phenotypes form a spectrum that ranges in severity from mild
to severe, where RDEB is usually more severe than DDEB. The severe phenotypes of the
disease are characterized by recurrent scarring of the skin and in the mouth and esophagus,
and often extracutaneous complications. Furthermore, excessive scarring can lead to the
fusion of fingers and toes. Eventually, patients with the more severe forms of RDEB are at
a high risk of developing squamous cell carcinoma, of which they usually die before the
age of 40 [3]. DDEB is mainly caused by glycine substitutions in type VII collagen in the
central triple helix domain of COL7A1 [4], which leads to impaired formation of the triple
helix structure and dominant negative interference of the mutant over the wild-type allele.
For RDEB patients with the most severe phenotype (RDEB-sev), the pathogenic variants
underlying the phenotype are, generally, null variants, leading to a premature termination
codon (PTC) and the complete absence of type VII collagen expression. The fourth and
least prevalent type of EB is KEB. KEB is characterized by trauma-induced blistering, which
mostly affects the extremities, skin atrophy, and poikiloderma. In addition, there is mucosal
involvement and photosensitivity. It is caused by pathogenic variants in the FERMT1 gene
(OMIM 173650), encoding the kindlin-1 protein that is localized in the focal adhesions of
the basal keratinocytes and plays important roles in cell adhesion and integrin signaling [5].
Curative and disease-modifying treatments for these diseases are being studied in-
tensively [6], but no truly curative treatments have been presented yet. Due to the broad
spectrum of genes and variants underlying EB, it is not possible to target every patient
with a single treatment strategy. As such, effective treatments for EB will have to target
patients/variants individually and will be as such highly personalized. An ideal therapy
for EB would correct the patient-specific variants through, for example, genome editing
strategies such as CRISPR-Cas9 [7–9]. Research into genome editing as a therapy for
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EB is currently ongoing, and researchers have reported success with genome editing of
COL7A1 [8] and LAMB3 [10]. However, while genome editing is proven successful in vitro
and ex vivo for EB, there are still hurdles to overcome [11]. Therefore, it is important to
consider alternatives that can be realized on shorter timescales with wider applicability.
One such approach could be exon skipping.
Table 1. Numbers of potentially skippable exons and pathogenic variants in those exons for each gene known to be involved
in Epidermolysis Bullosa.













Basal epidermal KRT14 Keratin 14 8 3 37.5 20 (39) 51.3
KRT5 Keratin 5 9 4 44.4 22 (24) 45.8
PLEC Plectin 39 17 43.6 43 (49) 87.8
KLHL24 Kelch-like familymember 24 6 2 33.3 0 (6) 0.0
EXPH5 Exophilin 5 6 0 0.0 0 (1) 0.0
CD151 Tetraspanin-24 7 5 71.4 2 (2) 100.0
DST Dystonin 24 11 45.8 22 (26) 84.6
Intralamina Lucida COL17A1 Type XVIICollagen 55 53 96.4 37 (38) 97.4
ITGB4 Integrin β4 39 20 51.3 15 (28) 53.6
LAMA3 Laminin α3 chain 75 25 33.3 24 (72) 33.3
LAMB3 Laminin β3 chain 22 5 22.7 36 (108) 33.3
LAMC2 Laminin γ2 chain 23 9 39.1 29 (73) 39.7
ITGA6 Integrin α6 25 10 40.0 2 (4) 50.0
ITGA3 Integrin α3 25 10 40.0 2 (7) 28.6
Sublamina Densa COL7A1 Type VII Collagen 118 107 90.7 270 (297) 90.9
Mixed levels FERMT1 Kindlin-1 14 9 64.3 12 (24) 50.0
1 An exon is considered skippable if the reading frame remains intact when the exon is ‘skipped’. 2 Only variants denoted as pathogenic in
ClinVar are included (online database of variants in the human genome. Clinvar is available at https://www.ncbi.nlm.nih.gov/clinvar/,
accessed on 7 October 2021). Between brackets the total number of variants in ClinVar for that gene.
2. Exon Skipping
Antisense oligonucleotide (ASO)-mediated exon skipping aims to remove an exon that
harbors a pathogenic variant from pre-messenger RNA (pre-mRNA) in order to mitigate
the effects of the variant. Exon skipping is facilitated through ASOs that are designed to
bind to the exon that contains the pathogenic variant and thereby mask it from the cellular-
splicing machinery. The end goal of exon skipping is the production of an alternatively
spliced mRNA in which the target (i.e., mutation-containing) exon is removed and the
open reading frame is restored. Depending on the size of the skipped exon, the resulting
protein will be shorter than wild type, which could have a negative impact on protein
function compared to the wild-type protein. However, according to studies on naturally
occurring exon skipping, in EB, this is still preferable to no protein being produced at
all [12]. Extensive research into splice-modulating antisense oligonucleotide therapies has
led to the approval of several ASO drugs by the FDA [13] and/or EMA, such as Nusinersen
for spinal muscular atrophy (OMIM 253300) and Eteplirsen [14] and Viltolarsen [15] for
Duchenne muscular dystrophy (OMIM 310200). Preclinical research into exon skipping for
COL7A1 and COL17A1 has demonstrated its potential as therapy for EB as well [16–19].
3. Antisense Oligonucleotides
ASOs are small (≈15−25 nucleotides) single-stranded molecules of RNA designed
to hybridize to specific messenger RNAs. Two classes of antisense mechanisms can be
distinguished depending on their mode of action. The first class of ASOs (RNA–DNA
hybrid ASOs) bind and degrade the target mRNA through RNase-H mediated degradation
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pathways. The second class of ASOs are splice switching ASOs, which affect pre-mRNA
splicing through the steric hindrance of small nuclear ribonucleoproteins [20]. Compounds
such as Inotersen act through the first mechanism category by targeting the TTR gene
involved in hereditary transthyretin-mediated amyloidosis (OMIM 105210), leading to
the degradation of mutant mRNA. In contrast, compounds such as Nusinersen, which
acts upon the SMN-2 gene involved in spinal muscular atrophy, and Golodirsen, which
targets DMD for Duchenne muscular dystrophy, are examples of the second mechanism
class of ASOs and act through steric blocking in order to induce alternative splicing [21].
ASO-mediated exon skipping for EB falls into this second category.
ASO design plays a crucial role in the overall efficacy of exon skipping therapy.
Important factors that must be considered and optimized before exon skipping therapies
can be considered for trials in patients include the following: the nature of the chemical
backbone and nucleotide modifications, the specific ASO sequence, and the choice of
delivery method. Many different chemical modifications of the nucleotide′s ribose have
been developed. To date, studies on exon skipping for EB have all used ASOs containing
2′-O-methyl modified bases (2′OMe) on a phosphorothioate (PS) backbone (2′OMe-PS),
2′-O-methoxyethyl (2′-MOE)-modified bases with phosphorothioate backbone (2′-MOE-
PS), and phosphorodiamidate morpholino oligomer (PMO) [16,17,19,22] (Figure 1). These
ASO chemistries have been tested in vivo [21,23], and each can confer different benefits to
pharmacokinetics and pharmacodynamics [21]. For example, the PS-backbone modification
confers nuclease resistance, reduced hydrophilicity, and enhanced protein binding, but it
is also known to carry a risk of coagulation inhibition and activation of the complement
immune system [24]. 2′-O-methoxyethyl (2′-MOE) has a lower chemistry-specific toxicity
compared to 2′-O-methyl (2′-OMe), while PMO has a somewhat lower potency compared
to other chemistries but a generally low safety risk and high stability [23,25,26]. Therefore,
careful consideration and analysis of the ASO chemistry for specific targets is essential.
However, it is difficult to directly compare the performance of different chemistries, as
delivery requirements can be chemistry-dependent [22].
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4. ASOs Targeting Mutated Exons in Epidermolysis Bullosa
Proof-of-concept studies have demonstrated the feasibility of the exon skipping ap-
proach for COL7A1 and COL17A1 (Table 2). Since 91% of its exons are in-frame and
potentially skippable, the early focus of exon skipping in EB has been on COL7A1, such as
by Goto et al., where the skipping of exon 70 of COL7A1 was induced using a 2′-OMe-PS
ASO [27]. Protein restoration, although at low efficiency (6% using IF), was observed
through immunofluorescence (IF) in primary RDEB keratinocytes transfected with ASOs
and in human skin equivalents (HSE), mimicking the characteristics of human skin. HSEs
were grown from RDEB patient keratinocytes and fibroblasts and were grafted on rats
treated with a single local injection of ASOs (30 µg) subcutaneously below graft. Exon 73
of COL7A1 is a hotspot for variants that underlie RDEB and DDEB [28] and is therefore
an interesting target for exon skipping therapy. QR-313 (Wings Therapeutics) is a 21 bp
2′-MOE-PS ASO designed for the skipping of COL7A1 exon 73 [17] that was in a phase
1/2 clinical trial for RDEB and DDEB (trial was terminated due to low patient enrollment).
QR-313 was shown to efficiently skip exon 73 in vitro and facilitate the synthesis of type VII
collagen in exon 73 mutated fibroblasts and keratinocytes (≈30−35% efficiency in ddPCR
analysis). QR-313, formulated in a carbomer hydrogel, was also applied topically to wound
beds in concentrations up to 200 nM in tape-stripped HSEs generated from both wild-type
and mutated exon 73 fibroblasts and keratinocytes. Using digital droplet PCR (ddPCR),
exon 73 skipping efficiency after 2 weeks of treatment of HSEs with 50 mg/cm2 QR-313
formulation was increased by ≈30−35% compared to control in the wounded dermis of
the RDEB HSEs. Other studies have demonstrated exon skipping for COL7A1 exons 10, 73,
80, and 105 [16,18,22,27,29].
In a separate study that targeted exon 73 and exon 80, 2′-OMe ASOs designed for
exon 80 reached up to 90% in primary cultured RDEB fibroblasts and 50% skip efficiency
in keratinocytes when assaying skip efficiency using RT-PCR and sequencing 48 h after
transfection [18]. For exon 73, efficiency was observed to be around 95% for primary
fibroblasts and 60% for keratinocytes. ASOs were supplied to these cells in doses of 50 nM,
100 nM, and 200 nM. Protein restoration levels in patient RDEB keratinocytes at the 50 nM
dosage reached 32% of type VII collagen expression in Western blot analysis, whereas this
was 19% for exon 80 [18]. Type VII collagen expression restoration was also observed by
IF nude mice xenografts when subcutaneously injected with 1 × 500 µg or 2 × 1000 µg
exon 73 skipping ASO, or 1 × 200 µg or 2 × 400 µg exon 80 skipping ASO directly under
the graft.
In a separate study regarding the splicing sequence of COL7A1, Ham et al. found that
PMO and 2′OMe-PS ASOs developed for exon 73 and exon 10 also showed exon skipping
in vitro as confirmed by Sanger sequencing for both 2′OMe-PS and PMO chemistries [22].
2′OMe-PS ASOs developed for exon 105 have also been shown to induce exon skipping
in mouse xenografts [16]. Primary cultured patient fibroblasts and keratinocytes were
grafted onto nude mice using a silicone grafting chamber [30]. The mice were subsequently
treated with daily systemic injections of 50 mg/kg ASO 5 days a week for 8 weeks. Exon
skipping was confirmed through RT-PCR and type VII collagen expression through IF
staining of type VII collagen (efficiency could not be quantified).
COL17A1 exclusively consists of in-frame exons and therefore is also attractive for exon
skipping. Ablinger et al. designed ASOs against COL17A1 exon 7 based on a patient with
intermediate JEB carrying a variant in this exon. ASO treatment restored type XVII collagen
expression in patient-derived primary cultured keratinocytes through exon 7 skipping [19].
The authors were also able to identify type XVII collagen expression at the cutaneous basal
membrane in HSEs generated from JEB keratinocytes pretreated with COL17A1 exon 7
ASOs. Type XVII collagen deposition was also observed in the cells treated with the ASOs.
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Table 2. ASOs developed to induce exon skipping in EB genes.








Chemistry 3 ASO Name Reference
COL7A1 10 CGGGCCUCAGGCACCAAGUUC 66 21 64 26.0 (2
′OMe) 2′-OMe-PS H10A(+65+85) [22]
COL7A1 10 CGGGCCUCAGGCACCAAGUUC 66 21 64 7.7 (PMO) PMO H10A(+65+85) [22]
COL7A1 10 CUUCCCCCGCACUGACCAGUCUC 65 23 N.A.
4 2′-OMe-PS H10D(+07-16) [22]
COL7A1 10 CUUCCCCCGCACUGACCAGUCUC 65 23 N.A.
4 PMO H10D(+07-16) [22]
COL7A1 70 CGCACACUUCCAGGC 66 15 32 8.3 (2
′OMe) 2′-OMe-PS [27]
COL7A1 73 CGUUCUCCAGGAAAGCCGAUG 57 21 5 8.1 (2
′OMe) 5 2′-MOE-PS QR-313 [17]
COL7A1 73 TCTTGCGCCCGACTTCCCGCTGGCACCTCT 67 30 20 26.6 (2
′OMe) 2′OMe [18]
COL7A1 73 UUCAGCCCGCGUUCUCCAGG 65 20 15 11.6 (2
′OMe) 2′-OMe-PS H73A(+16+35) [22]
COL7A1 73 UUCAGCCCGCGUUCUCCAGG 65 20 15 22.6 (PMO) PMO H73A(+16+35) [22]
COL7A1 73 CGCCCUUCAGCCCGCGUUCU 70 20 20 21.3 (2
′OMe) 2′-OMe-PS H73A(+21+40) [22]
COL7A1 73 CGCCCUUCAGCCCGCGUUCU 70 20 20 47.9 (PMO) PMO H73A(+21+40) [22]
COL7A1 73 CGCCCUUCAGCCCGCGUUCUCCAGG 72 25 15 49.9 (2
′OMe) 2′-OMe-PS H73A(+16+40) [22]
COL7A1 73 CGCCCUUCAGCCCGCGUUCUCCAGG 72 25 15 60.0 (PMO) PMO H73A(+16+40) [22]
COL7A1 80 TCCCAGACGTCCCAGGTTCTCCGG 67 24 N.A.
4 2′OMe [18]
COL7A1 105 GAUACCAGGCACUCCAUCCU 55 20 13 15.2 (2
′OMe) 2′OMe AON1 [16]
COL7A1 105 CAUGAAGCCAACAUCUCCUU 45 20 43 11.3 (2
′OMe) 2′OMe AON2 [16]
COL17A1 7 TTTGACTCCGTCCTCTGGTT 50 20 10 3.8 (2
′OMe) 2′-OMe-PS AON1 [19]
COL17A1 7 TCGTGTTTGACTCCGTCCTC 55 20 15 11.7 (2
′OMe) 2′-OMe-PS AON2 [19]
COL17A1 7 CTCCGTCCTCTGGTTGAAGA 55 20 5 42.4 (2
′OMe) 2′-OMe-PS AON3 [19]
1 Nucleotide position of first base of the target sequence as counted from the acceptor splice site in the target exon. 2 Exon efficiency
of the ASOs as predicted by eSkip-finder in percentage of transcripts, predicted under conditions of 2′OMe or PMO ASOs. 3 Chemical
modification of the ASO as described in the literature; see Figure 1A for structures. 4 Sequence could not be compared to eSkip-finder
predictions as it was out of the prediction range. 5 Sequence is of the 2′MOE variant, and thus, a comparison to 2′OMe does not convey
accurate information.
It is difficult to compare exon skipping efficiencies reported by different studies due to
the different methods and definitions used to ascertain these efficiencies. Standardization
of the methods used to measure exon skipping efficiency could improve our ability to
compare exon skipping efficiencies between studies and broaden our insights on what
makes for an optimal ASO sequence. For the optimization of ASOs for exon skipping in
Duchenne muscular dystrophy, ddPCR was recommended as the method of choice for
determining exon skipping efficiency, after comparing to other quantification methods
such as RT-qPCR and RNA sequencing [31,32]. ddPCR measures exon skipping efficiency
as a percentage of transcripts containing skipped exons. Preclinical research using cell
models is indispensable and provides a valuable indication of the success of exon skipping
treatment, specifically with regard to sequence design. However, it is difficult to reflect
the in vivo situation using cell models alone. Trialing ASO design, skipping efficiency,
expression levels, and delivery methods in more complex models such as skin xenografts
or ex vivo human skin models has the potential to better replicate the conditions of patient
skin and more precisely assess treatment efficacy.
As previously discussed, the applicability of exon skipping to EB is highly dependent
on the individual gene and specific details of pathogenic variants. However, the number of
EB patients (DEB or other) who can benefit from exon skipping treatment is not yet known.
For now, research is mostly focused on RDEB, as this is the more severe variant of DEB. In
DDEB, since type VII collagen is already expressed, it is conceivable that the introduction
of an exon-skipped allele in addition to wild-type and mutant alleles might even worsen
the phenotype instead of mitigating it. Therefore, it is questionable whether exon skipping
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as a therapy would benefit DDEB patients [33]. However, in contrast, QR-313 was shown
to improve epidermal attachment in DDEB skin models for exon 73 [17]. In addition, exon
73-skipped type VII collagen only rarely interacted with wild-type type VII collagen, which
means it did not negatively impact wild-type type VII collagen function but rather added
to it. It remains to be seen whether this effect is specific to the large exon 73 or if it holds
true for all in-frame exons in COL7A1. It also remains unknown whether the phenotypic
improvement is the same in vivo. If exon skipping proves to be a viable treatment strategy
for DDEB, the number of patients who could benefit from exon skipping therapy would
significantly increase.
5. Lessons from Natural Exon Skipping in Epidermolysis Bullosa
Natural exon skipping is a phenomenon in which exons are skipped due to the
pathogenic variants in a gene. Several case reports have shown that natural exon skipping
variants can lead to a milder type of EB than would be expected from the genotype. As the
goal of ASO-mediated exon skipping therapy is to improve the phenotype of EB to a milder
one, the potential therapeutic effect of ASO-mediated exon skipping can be appreciated by
looking at the phenotypes of patients carrying these natural exon skipping variants. Taking
COL7A1 as an example, the difference in the way each variant leads to the expression of a
phenotype can provide insight into if and how an exon skipping therapy can improve a
phenotype. With this goal in mind, a recent study specifically investigated natural exon
skipping variants in a cohort of 100 DDEB and 76 RDEB patients [33]. In these patients, 26
were found to carry variants in putative splice sites, and seven of these variants were found
to induce in-frame exon skipping. Another 20 COL7A1 natural exon skipping variants
were found in the literature. DDEB natural exon skipping variants caused phenotypes
resembling well-known DDEB phenotypes. In contrast, RDEB patients carrying natural
exon skipping variants were found to have generally milder phenotypes on the RDEB
spectrum than expected from their genotypes, with the exact phenotype dependent on
the level of type VII collagen expression. Therefore, it is predicted that the expression of a
shortened type VII collagen due to ASO-mediated exon skipping is more beneficial to the
patient than a complete absence of type VII collagen, showing that ASO-mediated exon
skipping is a viable treatment option for RDEB [12]. As discussed above, whether this is
also true for DDEB remains unclear.
A patient with a paternal COL7A1 exon 76 PTC variant (c.6311_6312delCT) and a
maternal COL7A1 exon 15 PTC (c.2005C>T) variant, leading to RDEB-sev in other patients,
was shown to have a milder-than-expected phenotype. An additional variant (c.1907G>T)
on the maternal allele, in cis with the c.2005C>T variant, weakened the exon 15 acceptor
splice site and induced in-frame skipping of exon 15 that resulted in the expression of a
shortened type VII collagen. Immunofluorescent staining showed lower expression levels
of type VII collagen (11%) compared to control, but even these levels were sufficient to
attenuate the phenotype toward a milder form. Other examples of natural exon skipping
are patients with RDEB and JEB carrying predicted PTC variants in COL7A1 and LAMB3,
respectively [34]. However, these variants did not behave as null variants and instead
induced natural exon skipping and hence milder-than-expected phenotypes. The COL7A1
variant c.2471dupG p.(Asn825Lysfs*41) and the LAMB3 variant c.2500C>T p.(Gln834*)
both occurred in purine-rich regions that may act as splicing enhancers. The proposed
mechanism was that the disruption of exonic splicing enhancer activity by these variants
led to natural exon skipping, which bypassed the PTCs and restored the reading frame i.e.,
exactly the mechanism by which ASO-mediated exon skipping aims to act.
Another example of natural exon skipping was observed in a patient with JEB interme-
diate who was compound heterozygous for PTC variants in exon 18 and 49 of COL17A1 [35].
Several non-blistering, healthy skin patches were observed on the patient′s arm. In IF
staining with three antibodies for type XVII collagen, a mosaic pattern was observed. Small
patches of the basal membrane zone resembled human normal control skin, as visualized
using exon 7 and exon 47–48 antibodies, while staining with an exon 48–49 antibody was
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completely negative. Selectively isolated type XVII collagen-positive keratinocytes showed
a reverse mutation in the exon 49 acceptor splice site that induced the skipping of this exon
and restoration of type XVII protein production.
Another case report studied a patient with EBS with pyloric atresia (EBS-PA) caused by
a maternal PLEC null variant (c.7396C>T) in exon 31 and a paternal null variant (c.7633C>T)
in exon 32 [36]. Whereas typical EBS-PA cases show a severe and lethal phenotype, this
case showed a milder phenotype with clinical improvement. While the specific mechanism
behind this phenomenon was not fully understood, it was presumed that the basis of this
milder phenotype lies in alternative splice variants of the PLEC transcript. RNA analysis
of PLEC in various human control tissues showed the presence of alternatively spliced
isoforms that were missing the rod domain encoded by exon 31 [36]. Deletion of the plectin
rod domain in C57Bl/6 mice revealed that the rod domain was not essential for the tissue
integrity function of plectin [37].
Together, these reports make the case for exon skipping as a promising treatment
strategy for EB patients with homozygous null variants. However, it remains elusive
whether exon skipping therapy would be suitable for treating dominant EB types. For
example, a 30 bp deletion in intron 6 of the KRT5 gene leading to in-frame skipping of
exon 6 was identified in a patient with EBS severe [38]. Exon 6 skipping led to deletion
of the highly conserved 2B domain, with the result that the keratin 5 protein acted in a
dominant negative fashion. Therefore, it seems unlikely that the introduction of an exon 6
skipped keratin 5 protein using ASOs would be beneficial for patients carrying dominant
KRT5 variants.
6. Selection of Epidermolysis Bullosa Genes and Exons for Targeting with
Exon Skipping
Selecting a gene and exon for the development of an exon skipping therapy comes
with many unanswered questions. To start, the exact numbers of patients and specific
variants may not always be known because we still lack a global EB database. Therefore, it
is difficult to estimate how many patients would benefit from the development of exon
skipping therapy for any given exon. There are also currently 16 known EB genes [2]
(Table 1). The large number of genes, and the number of exons within them, requires a
target prioritization method for selecting the best gene and exon. In-frame exons that have
not been found to contain pathogenic variants can be excluded. Consequently, all in-frame
exons that do contain pathogenic variants can be considered potential exon skipping targets.
In addition, as discussed above, it is expected that exon skipping therapy would be better
suited to treat bi-allelic null variants of EB genes within in-frame exons [33]. Therefore,
comparison of the relative in-frame exon count of a gene, and the number and frequency of
pathogenic variants in those in-frame exons may serve as a first indicator of the potential
of an exon skipping strategy, because the number of times a variant has been reported
can relate back to the number of patients. Thus, developing ASOs for these exons may
benefit a greater number of patients. Figures 2 and 3 provide a basic prioritization strategy
based on the genomic and mutational characteristics of the EB genes. These preliminary
characteristics provide only the first step in gene and exon selection. They do not take ASO
design or protein function into account; furthermore, complexity is introduced through
different isoforms of proteins. PLEC possesses eight isoforms where the first exon is
different in each transcript, and the exon count of all non-coding exons comes down to
39 exons.
Some in-frame exons may be amenable to exon skipping, but these may also encode
essential protein domains that are indispensable for proper protein function, effectively
making them un-skippable. Therefore, exons of interest must always be considered with
keeping such limitations in mind. For example, at only 31.2 kb in length with 118 exons,
the COL7A1 gene is relatively compact (Figure 4): 107 (91%) of these exons are in-frame
and potentially skippable, and 270 pathogenic variants are located in these in-frame exons,
as recorded in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) accessed on 7 October
2021. However, the process does not stop there. A large part of COL7A1 also consists of
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repeating elements, which could complicate the design of exon-specific ASOs. On the other
hand, it could be argued that the high repetitiveness of these exons means that the absence
of one exon would not have a large impact on the function of the protein as a whole [29]. A
further complication in ASO design for COL7A1 are the guanine nucleotide repeats in the
collagen triple-helix domain, with a high GC percentage limiting the locations for which
ASOs can be specifically designed (see supplement for other EB genes).
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of exons per gene. Green tiles represent in-frame and potentially skippable exons, red tiles represent
non-skippable (out-of-frame) exons. The number in each tile is the number of pathogenic variants as
recorded in ClinVar on 7 October 2021. For this figure, the canonical consensus coding sequences are
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7. Development of ASOs for Targeting Exon Skipping in Epidermolysis Bullosa
The development of an exon skipping ASOs starts with identifying the target sequence.
Several important criteria that need to be considered when designing an ASO sequence
have emerged from previous studies [21,39,40]. In a study examining effective ASO
sequence design, in vitro analysis of splice-modulating ASOs showed that effective ASOs
are located closer to the acceptor splice site [40]. To further increase the exon skipping
efficiency, ASOs should target sequences important to splice regulation, such as exon
splice enhancers, and contain a relatively high (>50% [39]) GC-content. Nearest neighbor
melting temperature should be considered to increase the stability. Finally, the ability of an
ASO to form secondary structures should be investigated, because these could interfere
with binding to the mRNA [40]. Exclusion criteria such as stretches of three or more G
or C nucleotides should also be taken into account. These are generally avoided in ASO
sequences because they risk binding too strongly to serum proteins and off-target sites [41].
Based on these criteria, in silico predictions can be made about the most efficient ASOs.
However, whether these predicted ASOs are indeed the most efficient ASOs can only be
determined through a laborious empirical process of trialing many different sequences.
Thus far, this is the method by which all ASOs used in preclinical studies for EB have
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been designed. A newly developed in silico tool may help broaden our perspective in
this process.
eSkip-finder is a recently published online machine-learning based tool for finding
optimal ASO sequences for exon skipping [42]. To understand the power of eSkip-Finder
in designing ASOs for EB, we compared the sequences of ASOs designed by ourselves
and other groups based on in silico predictions and determined by empirical studies to
the optimal ASO sequences predicted by eSkip-Finder. Comparisons between predicted
and published sequences targeting COL7A1 and COL17A1 provided remarkably different
results (Table 2): eSkip-Finder predicted that the ASOs designed in the classical way
should have low exon-skipping efficiency, while other sequences that were avoided during
classical design for reasons such as G/C triplicates were predicted to have much higher
efficiency. However, the ASO sequences predicted by eSkip-Finder are a machine-learning
prediction and only account for predicted skip efficiency. The tool does not account for
whether an ASO can actually be synthesized or for the inclusion of guanine or cytosine
repeats. Nonetheless, the optimal ASOs predicted by eSkip-Finder are worth exploring
during the design of new ASOs for exon skipping to be trialed next to classically designed
ASOs in order to test whether any further optimizations with regard to skipping efficiency
for EB can be achieved.
Targeting specific exons for skipping is challenging, as reported by Ham et al. [22].
COL7A1 splice sites are not strongly defined. ASOs for COL7A1 designed to target exon
73 led to aberrant splicing of the mRNA, leading to the inclusion of intron 76 into the
mature RNA. The mechanism behind this intron retention is not yet fully understood.
However, it indicates that it is crucial to experimentally verify that ASOs produce the
desired results in a laboratory setting, which is an additional criterion to consider in the
design of ASO sequences.
8. Delivery of ASO Therapies
Exon skipping as a treatment is limited in that it would require repetitive treatments
due to the transient nature of ASOs. Therefore, it is important to carefully consider
the way in which ASO therapies are delivered in vivo. The topical application of ASOs
to wound beds using carbomer hydrogel in vitro and in ex vivo porcine skin [17] or
liposomes in vitro [19], has been shown to induce efficient exon skipping in cells at the
site of application. The administration of ASO to the wound bed has the increased benefit
of directly being applied to the exposed cells where exon skipping should be induced.
However, the topical application of ASOs is not a systemic treatment. While improved
wound healing and skin stabilization would improve the quality of life for patients, a
systemic treatment has the potential to prevent blistering through skin stabilization in
addition to treating other (mucosal) tissues inaccessible to topical treatment. Systemic
treatment has been shown to work in xenograft mice [16], but the delivery of a systemic
treatment does provide a challenge.
Liposomes are not a feasible strategy for systematic delivery given the possibility of
non-specific uptake in different tissues. Furthermore, ASOs applied in a systemic fashion
will also have to contend with difficulties such as the potential for systemic and local
adverse events, such as the accumulation of ASOs in unintended tissues leading to pro-
teinuria, inflammatory responses, and inhibition of coagulation or thrombocytopenia [21].
The exact chemical modifications of ASOs also play an important role in the choice of
delivery, which is out of the scope of this review. Therefore, more research into delivery
methods and ASO chemistry is crucial to target a systemic treatment specifically to the
keratinocytes and fibroblasts. To solve the systemic delivery issue, the development of a
basal keratinocyte-specific marker molecule may be required. This concept has been shown
before using GalNac conjugates for targeting hepatocytes [43], and multiple ASO-GalNac
conjugate-based treatments have been used in trials [44]. A notable example of an approved
drug using the GalNac conjugate system includes Givosiran, which is a GalNac-siRNA
conjugate targeting ALAS1 in order to treat acute hepatic porphyria [45].
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9. Concluding Remarks and Future Perspectives
While exon skipping as a treatment for genetic diseases is an established strategy, it
is still in a maturing phase with regard to EB. Our review provides a perspective on the
application of exon skipping as a treatment strategy for EB and provides insight into the
criteria required for the development of these novel therapies. The groundwork for exon
skipping has been laid, and current research is moving more toward clinical applications.
ASO-mediated exon skipping as a treatment strategy for EB has a promising outlook, espe-
cially for RDEB and JEB. Exon skipping therapy also offers a more promising short-term
perspective compared to treatment strategies such as genome editing. Favorable results in
studies pertaining to ASO development for the exon skipping of COL7A1 and COL17A1
may translate to an increased understanding of the applications of exon skipping for EB in
general, and the streamlined development of ASO-mediated exon skipping therapies for
other forms of EB. However, while ASO-mediated exon skipping for EB is about to make
the jump to the clinical setting, there are still some challenges to overcome that require
further study such as the in vivo effect of EB exon skipping therapy. Furthermore, ASOs
for exon skipping in EB need to be developed in a mutation-specific manner. The small
cohort of patients who could benefit from a specific ASO treatment makes it commercially
uninteresting to develop. On the other hand, patients who can be treated with ASOs can
have a vastly improved quality of life. In addition, bringing exon skipping for EB to clinical
practice using the classic therapy development route is impossible, as any trials will be
small scale or even n = 1. Fortunately, alternative N-of-1 routes to bring such small-scale
treatments to patients are being explored increasingly at the moment [46]. An example of
an ASO developed in this way is Milasen, which was specifically developed for a single pa-
tient suffering from neuronal ceroid lipofuscinosis [47]. The implementation of regulations
that include special considerations for individualized treatments will hopefully pave the
way for developing such n-of-1 therapies for patients who would otherwise go untreated,
such as exon skipping for EB [46].
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